Redhill Biopharma

RDHL

Current ValuationThe current P/E ratio is -1.20, below the reasonable range, cheaper than 85.06% of the time in the past 3 years, and the industry ranks 113/255, the industry Median -1.27.

-1.2xP/E
Stock price$0.47Earnings per share$-0.39

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-55.58x148.12%$58.03B
BAYRYUSBayer
-23.88x--$48.18B
BAYZFUSBayer Aktiengesellschaft
-24.60x--$49.64B
VTRSUSViatris
-48.91x107.75%$20.09B
ELANUSElanco Animal Health
-56.14x129.36%$11.17B
AXSMUSAxsome Therap
-47.28x26.61%$9.06B
VREOFUSVIREO GROWTH INC
-127.80x--$8.58B
CURLFUSCuraleaf Holdings, Inc.
-144.92x--$7.54B
BLTEUSBelite Bio
-61.41x29.87%$6.29B
DFTXUSDefinium Therapeutics
-13.33x53.61%$4.71B
MANEUSVeraDermics
-44.45x97.44%$4.64B
EWTXUSEdgewise Therapeutics
-21.79x137.29%$4.30B
RGCUSRegencell Bioscience
-301.05x--$3.52B
AMLXUSAmylyx Pharmaceuticals
-22.64x1.76%$3.44B
TARSUSTarsus Pharmaceuticals
-69.50x205.82%$3.23B
ELVNUSEnliven Therapeutics
-28.61x6.39%$3.03B
MBXUSMBX Biosciences
-25.19x31.12%$2.63B
SUPNUSSupernus Pharma
-22.77x70.59%$2.50B
BHCUSBausch Health
-2.09x172.62%$2.30B
PHVSUSPharvaris BV
-11.21x10.70%$2.22B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.